Nurix Therapeutics (NRIX) Revenue (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Revenue data on file, last reported at $6.3 million in Q1 2026.

• Quarterly Revenue fell 66.12% year-over-year to $6.3 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $42.7 million (down 24.27% YoY) and the FY2025 annual result came in at $84.0 million, up 53.95% from the prior year.
• Revenue eased to $6.3 million in Q1 2026 per NRIX's latest filing, from $13.6 million in the prior quarter.
• Across five years, Revenue topped out at $30.7 million in Q2 2023 and bottomed at $6.3 million in Q1 2026.
• The 5-year median for Revenue is $12.7 million (2023), against an average of $13.6 million.
• The widest annual swing landed in 2023, when Revenue jumped 168.33%; it then slumped 66.12% in 2026.
• Tracing NRIX's Revenue over 5 years: stood at $6.8 million in 2022, then surged by 123.49% to $15.2 million in 2023, then slipped by 12.37% to $13.3 million in 2024, then gained by 2.21% to $13.6 million in 2025, then plunged by 53.95% to $6.3 million in 2026.
• Per Business Quant, the three latest NRIX Revenue figures stand at $6.3 million (Q1 2026), $13.6 million (Q4 2025), and $7.9 million (Q3 2025).

Peer Comparison